Capricor Therapeutics (NASDAQ:CAPR) CFO Sells $792,500.00 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at $260,669.10. This represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Anthony Bergmann also recently made the following trade(s):

• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Price Performance

CAPR opened at $34.38 on Thursday. The business has a 50 day simple moving average of $31.33 and a 200-day simple moving average of $23.14. The stock has a market capitalization of $1.99 billion, a P/E ratio of -15.21 and a beta of 0.48. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Research analysts anticipate that Capricor Therapeutics, Inc. will post 0.01 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. Wall Street Zen cut Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. B. Riley Financial lifted their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Piper Sandler reaffirmed an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, March 10th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CAPR. Suvretta Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics during the fourth quarter worth $49,062,000. RA Capital Management L.P. purchased a new position in Capricor Therapeutics during the fourth quarter worth $43,516,000. Darwin Global Management Ltd. purchased a new position in Capricor Therapeutics during the fourth quarter worth $23,168,000. Finally, SB Capital Management Inc purchased a new position in Capricor Therapeutics during the fourth quarter worth $11,544,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.